MedTrace Logo

Safety and Efficacy Study of DAV132 in Healthy Volunteers

NCT02176005 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2020-02-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether DAV132 is safe and effective for capturing fecal residues of moxifloxacin in healthy volunteers.

Conditions

  • Healthy

Interventions

DEVICE

DAV132

DAV132 is associated to moxifloxacin or it is evaluated alone

DRUG

Moxifloxacin

Moxifloxacin is used alone or associated to DAV132

OTHER

Negative Control

Moxifloxacin is used alone

Sponsors & Collaborators

  • Da Volterra

    lead INDUSTRY

Principal Investigators

  • Xavier Duval, MD · CIC Bichat, Paris France

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-10-31
Completion
2014-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02176005 on ClinicalTrials.gov